Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Effekten av IVMED-85 på pediatrisk närsynthet

12 november 2026 uppdaterad av: iVeena Delivery Systems, Inc.

A Randomized, Vehicle-Controlled, Double-Masked Study of the Efficacy and Safety of IVMED-85 Ophthalmic Solution for the Treatment of Pediatric Myopia

To evaluate the efficacy and safety of a 12-month course of IVMED-85 ophthalmic solution on the treatment of pediatric myopia.

The main aims are:

  • Assess the efficacy of a 12-month treatment of IVMED-85 in slowing myopia progression in pediatrics
  • Assess the safety of a 12-month treatment of IVMED-85

Participants will use eyedrops twice a day for 12 months. Researchers will compare IVMED 85 (2 doses) to a placebo.

Studieöversikt

Detaljerad beskrivning

This is a multicenter, randomized, vehicle-controlled, double-masked study conducted in the United States (US) in subjects with pediatric myopia in both eyes.

Approximately 144 subjects will be stratified by age group (5 to 7 years of age; 8 to 10 years of age) and randomized (1:1:1) to one of three investigational products (IPs): IVMED-85 ophthalmic solution low-dose or high-dose; or vehicle ophthalmic solution. The study will use stratified block randomization by age group, with a 1:1:1 allocation within each stratum.

Subjects will administer their assigned IP in both eyes two times a day (BID) for approximately 12 months before entering a non-interventional period of approximately 4 months. Subjects will administer their IP under the supervision of a parent/guardian. Subjects who cannot independently apply IP can have their parent/guardian administer IP for them.

The study eye (SE) will be the more myopic eye. If both eyes are equally myopic in spherical equivalent, the eye with more spherical myopia (and less astigmatism) will be chosen as the study eye. If both eyes are equally myopic and astigmatic, the right eye (OD) will be the study eye.

A Data and Safety Monitoring Committee (DSMC) will be convened and will provide ongoing review of cumulative safety data throughout study conduct, inclusive of a Month 4 interim analysis of unmasked safety data.

Studietyp

Interventionell

Inskrivning (Beräknad)

144

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

5 år till 10 år (Barn)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Subjects who meet all the following inclusion criteria at Visit 1 (Screening/Baseline) will be eligible to enroll in the study. Ocular criteria apply to both eyes.

  1. Are 5 to 10 years of age
  2. Have a minimum body weight of 15.45 kg (34 lbs)
  3. Willing and able to provide informed consent and/or assent and relevant privacy authorization(s) Note: Informed consent is required from a parent/guardian and assent will be collected from subjects as appropriate for their age and maturity level. Assent may be waived for subjects under 6 years of age
  4. Willing and able to comply with clinic visits and study-related procedures
  5. Able to successfully administer ophthalmic solution or have a parent/guardian who can administer ophthalmic solution
  6. Willing and able to discontinue use of topical ocular medications for the duration of study participation Note: Artificial tears are allowed but must not be used within 30 minutes before or after administration of IP
  7. Have refractive error as determined by cycloplegic autorefraction: myopia -0.50 D to -7.0 D (spherical equivalent); astigmatism ≤3.00 D; anisometropia ≤2.00 D
  8. Have BCVA ≤0.3 logarithm of the minimum angle of resolution (logMAR) (20/40 Snellen or better)
  9. Have corneal thickness between 450 and 680 μm
  10. Have IOP ≤22 mmHg
  11. Have axial length ≥20 mm and ≤27 mm
  12. Willing to forgo swimming in an indoor pool within 1 hour before or after IP administration for the duration of study participation
  13. Willing to forgo swimming in an indoor pool within 1 hour before a clinic visit for the duration of study participation

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: IVMED-85 Low Dose

Total subjects n=48, IVMED-85 low dose BID for 12 months

Eye drop

Experimentell: IVMED-85 High Dose

Total subjects n=48, IVMED-85 high dose BID for 12 months

Eye drop

Placebo-jämförare: Placebo

Total subjects n=48, placebo BID for 12 months

Eye drop

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Refractive error change from baseline at Month 12
Tidsram: Baseline compared to month 12

Change from baseline in myopic refractive error (spherical equivalent as determined by cycloplegic autorefraction) in the SE at Month 12

Baseline compared to month 12

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Refractive error (spherical equivalent as determined by cycloplegic manifest refraction)
Tidsram: From screening to the end of treatment at 12 months

Change from baseline in myopic refractive error (spherical equivalent as determined by cycloplegic manifest refraction) in the SE at Month 12

From screening to the end of treatment at 12 months
Change in optical biometrics
Tidsram: From screening to the end of treatment at 12 months

Change from baseline in keratometry, axial length, and vitreous chamber depth in the SE at all post-baseline visits

From screening to the end of treatment at 12 months
Refractive error at non-final study visits
Tidsram: From screening to the end of treatment at 12 months

Change from baseline in myopic refractive error (spherical equivalent as determined by cycloplegic autorefraction and cycloplegic manifest refraction) in the SE at all post-baseline visits other than Month 12

From screening to the end of treatment at 12 months
Sub foveal choroidal thickness
Tidsram: From screening to the end of treatment at 12 months

Change from baseline in sub foveal choroidal thickness in the SE at Month 12

From screening to the end of treatment at 12 months
Accommodative amplitude in the spherical equivalent
Tidsram: From screening to the end of treatment at 12 months

Change from baseline in accommodative amplitude in the SE at Month 12

From screening to the end of treatment at 12 months

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Progression of high myopia
Tidsram: From screening to the end of treatment at 12 months

Proportion of subjects with baseline myopia of -5 to -5.75 D progressing to -6.25 or worse at Month 12

From screening to the end of treatment at 12 months
Progression of prospectively identified progressive myopia
Tidsram: From screening to the end of treatment at 12 months

Myopia progression at Month 12 in subjects prospectively identified at baseline as having progressive myopia, defined as an increase of 0.50 D or more in cycloplegic refractive myopia in the previous year based on historical chart records

From screening to the end of treatment at 12 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studiestol: Bala Ambati, iVeena Delivery Systems, Inc.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 februari 2027

Primärt slutförande (Beräknad)

1 februari 2029

Avslutad studie (Beräknad)

1 juni 2029

Studieregistreringsdatum

Först inskickad

23 februari 2023

Först inskickad som uppfyllde QC-kriterierna

7 mars 2023

Första postat (Faktisk)

9 mars 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

16 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

12 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • IVNA 26-01

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera